Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Aratana Therapeutics to Participate at Upcoming Investment Conferences

Share:

LEAWOOD, Kan., Feb. 13, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ:PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, plans on attending the following upcoming investment conferences:

Aratana Therapeutics logo

Bank of America Merrill Lynch 2019 Animal Health Summit
Monday, February 25 in New York City
Dr. Ernst Heinen (Chief Development Officer) will discuss the Company's development strategy and key pipeline programs.

Cowen Health Care Conference 
Wednesday, March 13 at 10:40 a.m. ET in Boston
Listen to presentation webcast 
Craig Tooman (President and Chief Executive Officer) and the management team will present and host one-on-one meetings with financial analysts and investors.

Barclays Global Healthcare Conference 
Thursday, March 14 at 10:15 a.m. ET in Miami
Listen to presentation webcast 
Craig Tooman (President and Chief Executive Officer) will present and host one-on-one meetings with financial analysts and investors.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats. As a pioneer in pet therapeutics, Aratana's mission is to deliver safe and effective therapeutics that elevate the standard of care in veterinary medicine. We work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
ir@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
media@aratana.com
(913) 353-1050

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-participate-at-upcoming-investment-conferences-300794612.html

SOURCE Aratana Therapeutics, Inc.

View Comments and Join the Discussion!